Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?
- PMID: 16763267
- PMCID: PMC1476741
- DOI: 10.1136/bmj.332.7554.1393
Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?
Comment on
-
Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.BMJ. 2006 May 20;332(7551):1177-81. doi: 10.1136/bmj.38803.528113.55. Epub 2006 May 5. BMJ. 2006. PMID: 16679330 Free PMC article.
References
-
- Fuseau E, Kempsford R, Winter P, et al. The integration of population approach into drug development: a case study, naratriptan. European Commission Conference, Geneva 1997: 204-14: EUR 17611EN.
-
- Millson DS. The clinical pharmacokinetics of the triptans: what are the important clinical issues? In: Humphrey P, ed. International headache research seminars series. Copenhagen, 2001: 57-71.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources